Vyne Therapeutics IncNASDAQ:VYNE
- LAST PRICE2.5000
- TODAY'S CHANGE (%)0.0300 (1.2146%)
- Bid / Lots2.0400/ 4
- Ask / Lots2.8000/ 2
- Open / Previous Close2.5300 / 2.4700
- Day Range
- 52 Week Range
- Volume15,899
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VYNE |
|---|---|---|
| 09:41 ET | 125 | 2.53 |
| 09:48 ET | 200 | 2.47 |
| 09:52 ET | 400 | 2.5 |
| 09:54 ET | 592 | 2.5 |
| 09:56 ET | 600 | 2.5 |
| 09:57 ET | 790 | 2.49 |
| 10:01 ET | 608 | 2.49 |
| 10:03 ET | 592 | 2.48 |
| 10:35 ET | 250 | 2.48 |
| 11:27 ET | 800 | 2.49 |
| 11:29 ET | 500 | 2.47 |
| 11:44 ET | 359 | 2.4314 |
| 12:14 ET | 800 | 2.422 |
| 12:25 ET | 360 | 2.42 |
| 12:27 ET | 400 | 2.42 |
| 12:54 ET | 350 | 2.4301 |
| 01:46 ET | 200 | 2.5 |
| 01:48 ET | 100 | 2.5137 |
| 01:55 ET | 100 | 2.48 |
| 02:02 ET | 1396 | 2.51 |
| 02:15 ET | 555 | 2.4606 |
| 02:24 ET | 454 | 2.465 |
| 03:12 ET | 200 | 2.48 |
| 03:18 ET | 600 | 2.47 |
| 03:57 ET | 424 | 2.5 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vyne Therapeutics Inc | 34.8M | -0.4x | --- |
Bright Green Corp | 35.0M | -2.7x | --- |
Eyenovia Inc | 36.2M | -0.9x | --- |
Cyclo Therapeutics Inc | 37.0M | -0.9x | --- |
Lexaria Bioscience Corp | 28.2M | -3.4x | --- |
NDT Pharmaceuticals Inc | 41.6M | 0.0x | --- |
Company Information
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Contact Information
- Headquarters
- 685 Route 202/206 N., Suite 301BRIDGEWATER, NJ, United States 08807
- Phone
- 650-486-1416
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- David Domzalski
- Chief Financial Officer, Treasurer
- Tyler Zeronda
- Chief Scientific Officer
- Iain Stuart
- Chief Legal Officer, General Counsel, Secretary
- Mutya Harsch
- Lead Independent Director
- Patrick Lepore
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.8M |
|---|---|
Revenue (TTM) | $424.0K |
Shares Outstanding | 14.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-6.84 |
Book Value | $6.29 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 82.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,900.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
